12/4
08:12 am
ucbjy
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
Low
Report
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
11/5
07:32 am
ucbjy
UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
11/3
04:00 pm
ucbjy
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Low
Report
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
10/29
12:00 pm
ucbjy
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
Low
Report
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
10/29
07:00 am
ucbjy
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
Low
Report
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
10/28
06:19 am
ucbjy
UCB (OTCMKTS:UCBJY) was upgraded by analysts at Jefferies Financial Group Inc. to a "moderate sell" rating.
Medium
Report
UCB (OTCMKTS:UCBJY) was upgraded by analysts at Jefferies Financial Group Inc. to a "moderate sell" rating.
10/25
11:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
Low
Report
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
10/14
07:31 am
ucbjy
Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior [Yahoo! Finance]
Low
Report
Final analysis of open-label extension (OLE) study of FINTEPLA® (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy & Behavior [Yahoo! Finance]
10/13
07:11 am
ucbjy
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) [Yahoo! Finance]
Low
Report
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) [Yahoo! Finance]
10/13
07:00 am
ucbjy
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Low
Report
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
10/7
09:03 am
ucbjy
Boosting clinical trial success in Alzheimer's, Parkinson's and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks [Yahoo! Finance]
Low
Report
Boosting clinical trial success in Alzheimer's, Parkinson's and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks [Yahoo! Finance]
9/17
07:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
Low
Report
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
9/17
07:00 am
ucbjy
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
Low
Report
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
9/10
08:22 am
ucbjy
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care [Yahoo! Finance]
Low
Report
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care [Yahoo! Finance]
9/10
08:00 am
ucbjy
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
Low
Report
Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care